Literature DB >> 8249044

Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.

R W Jelliffe1, A Schumitzky, M Van Guilder, M Liu, L Hu, P Maire, P Gomis, X Barbaut, B Tahani.   

Abstract

The role of population pharmacokinetic modeling is to store experience with drug behavior. The behavior of the model is then correlated with the clinical behavior of the patients studied, permitting selection of a specific serum level therapeutic goal that is based on each individual patient's need for the drug and on the risk of adverse reactions, both of which must be considered. A dosage regimen is then computed to achieve that goal with maximum precision. The patient should not run a greater risk of toxicity than is justified, and should obtain the maximum possible benefit within the acceptable risk. The regimen is given and the patient monitored.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249044

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  36 in total

Review 1.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

Authors:  A D Kashuba; C H Ballow; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.

Authors:  S Corvaisier; P H Maire; M Y Bouvier d'Yvoire; X Barbaut; N Bleyzac; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

5.  Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.

Authors:  A A Vinks; J W Mouton; D J Touw; H G Heijerman; M Danhof; W Bakker
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 6.  Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.

Authors:  Sam G Raney; Thomas J Franz; Paul A Lehman; Robert Lionberger; Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

Review 7.  Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.

Authors:  Tony K L Kiang; Catherine M T Sherwin; Michael G Spigarelli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

8.  Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance.

Authors:  Roger W Jelliffe; Alan Schumitzky; David Bayard; Xiaowei Fu; Michael Neely
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

9.  Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants.

Authors:  Frédéric Leger; Jean Debord; Yann Le Meur; Annick Rousseau; Mathias Büchler; Gérard Lachâtre; Gilles Paintaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.